The role of ERa non-nuclear signaling in female heart failure was investigated, using a novel mouse line in which ERa non-nuclear signaling was selectively disrupted by inhibiting the interaction between ERa and striatin, a scaffold protein residing at caveolae.
SUMMARY
Using genetically engineered mice lacking estrogen receptor-a non-nuclear signaling, this study demonstrated that estrogen receptorÀa non-nuclear signaling activated myocardial cyclic guanosine monophosphate-dependent protein kinase G and conferred protection against cardiac remodeling induced by pressure overload. This pathway was indispensable to the therapeutic efficacy of cyclic guanosine monophosphateÀphosphodiesterase 5 inhibition but not to that of soluble guanylate cyclase stimulation. These results might partially explain the equivocal results of phosphodiesterase 5 inhibitor efficacy and also provide the molecular basis for the advantage of using a soluble guanylate cyclase simulator as a new therapeutic option in post-menopausal women. This study also highlighted the need for female-specific therapeutic strategies for heart failure. Phase III clinical study (11) . It is of significant clinical importance to determine whether its efficacy is affected by estrogen conditions.
Estrogen plays a significant role in maintaining homeostasis of the cardiovascular system and vascular protection in women (12) (13) (14) (15) (16) (17) (18) (19) . Estrogen and its re- Research Institute, Tufts Medical Center, Boston, Massachusetts; and the involve activation of kinase signaling, which leads to rapid cellular responses, known as non-nuclear signaling (20) . ERa is one of the predominant ER subtypes, which has both nuclear and non-nuclear actions. The roles for ERa nuclear actions have been clarified using unique mouse models of ERa, including a model lacking AF-1 function (ERa AF-1 0 mice) and a model lacking AF-2 function (ERa AF-2 0 mice), as well as a complete gene deletion model (21, 22) . In particular, the dissection of ERa AF-2 0 that lacks nuclear function has provided evidence that the nuclear actions of ERa mediate protective effects against atherosclerosis, diabetes, and bone demineralization, which are conferred by estrogen (22) (23) (24) (25) .
In contrast, non-nuclear actions of ERa have been shown to mediate endothelial NO production, vasodilatation, and endothelial healing (re-endothelialization) from the study of a mouse that had a point mutation at its palmitoylation site (C451A-ERa), and therefore, a membrane-specific loss of function (20, 26) . Other studies used pharmacological tools to study non-nuclear actions, including estrogen dendrimer conjugates (EDCs) or pathway-preferential estrogens (PaPEs) (20) , and demonstrated the role for vasculo-protection and endothelial NO production without growing uterine or breast cancer cells (21, (27) (28) (29) (30) given by oral gavage every day for 3 weeks as described previously (34) .
The KRR KI/KI mice (KRR knock-in mutant ERa) were generated by GenOway (Lyon, France) as previously described (35) . The mutations were introduced in the exon 3 of ESR1, replacing amino acids 235K, 237R, and 238R: GCC, GCT, and GCA of mouse ERa (corresponding 231K, 233R, and 234R of human ERa) with alanine. These mutations were located in region C, the DNA-binding domain of ERa. Heterozygous male and female animals were mated, and all of the offspring were genotyped by polymerase chain reaction as previously described (35 O v a r i e c t o m y . Ovariectomy was performed in female mice at the age of 6 to 8 weeks by a standard bilateral back approach procedure (36, 37) . Briefly, animals were anesthetized with an intraperitoneal injection of 100 mg/kg of etomidate and placed in a prone position. Two small skin incisions (1 cm in length) were made on both lateral back sides, caudal to the last rib and 1 cm lateral from the vertebra. To reach the peritoneal space, the body wall and peritoneal muscle layer were incised. The ovary was identified with oviducts, uterus, and fat tissues, and then exteriorized with forceps. After a ligature was applied between the ovary and the edge of uterine horn for hemostasis, the ovary was carefully excised.
E s t r o g e n r e p l a c e m e n t . One week after ovariec- (10) . Studies were performed by investigators blinded to genotypes and heart conditions. Serial studies were performed on the day of and at 1 and 3 weeks after TAC surgery.
HEMODYNAMIC STUDY USING PRESSURE VOLUME ANALYSIS. In vivo LV function was assessed by pressureÀvolume analysis in anesthetized mice as previously described (6,33). The LV apex was exposed through an incision between the seventh and eighth 
CARDIOMYOCYTE ISOLATION AND NOS ACTIVITY
MEASUREMENT. Cardiomyocytes were isolated from KRR WT/WT and KRR KI/KI mouse hearts as previously described (38) . Briefly, the heart was quickly excised and retroperfused through the ascending aorta with For measuring E2 concentration in heart tissue, we followed the published protocol by Iorga et al. (39) .
LV samples were trimmed in 80 to 100 mg of tissues.
Samples were then snap frozen, pressed into powders, and were diluted in E2 enzyme immunoassay buffer at a concentration of 100 mg powder/ml buffer.
Amounts per 100 mg heart tissue were calculated.
RNA AND PROTEIN ANALYSIS. Total RNA was extracted from mouse LV heart samples by using (Toyobo Inc., Osaka, Japan), and relative expression levels of target genes were measured using Light Cycler480 (Roche Inc., Basel, Switzerland) as previously described (38, 40) . Each sample was run in duplicate, and the results were normalized to glyceraldehyde 3-phosphate dehydrogenase.
PKG ACTIVITY ANALYSIS. An enzyme immunoassay colorimetric assay (CycLex, MBL International Corporation, Woburn, Massachusetts) was performed to
Cardioprotective Roles of ER-a Non-Nuclear Signaling evaluate PKG activity as previously described. Proteins were extracted from whole heart samples according to the previous description (2).
HISTOLOGY. Heart samples were fixed with 10% formalin and embedded in paraffin. Samples were sliced into 4-to 5-mm slices. Sections were stained with Picrosirius red for interstitial fibrosis and fastgreen for counterstaining. The LV short axis at the levels of papillary muscle was analyzed. Cardiomyocyte cell size was measured using wheat germ 
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Cardioprotective Roles of ER-a Non-Nuclear Signaling physiological results supported the necessity of ERa non-nuclear signaling in heart failure remodeling and in the efficacy of PDE5i. Figure 4A ).
The CTGF induction by TAC was also inhibited by E2
or PDE5i þ E2 in KRR WT/WT hearts. Interestingly, in 
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Cardioprotective Roles of ER-a Non-Nuclear Signaling to 5E, Supplemental Figure 10A ) was also potently improved by sGC stimulation without altering heart rate or LV afterload (Ea) (Supplemental Figures 10B   and 10C) . Importantly, the anti-remodeling benefits from sGC stimulator treatment were associated with a marked increase in myocardial PKG activity ( Figure 5F ). Figures 11 and 12 ). These results suggested that enhancing cGMP pathways with a sGC stimulator improved cardiac remodeling during pressure overload without affecting locomotor activities or VO 2 .
DISCUSSION
In the present study, we used a novel genetically engineered mouse model and demonstrated that ERa non-nuclear signaling is a pivotal contributor to the protection against cardiac remodeling conferred by estrogen and is essential to the therapeutic efficacy of cGMP-PDE5i in heart failure but not to that of sGC stimulation (Supplemental Figure 13) . Fukuma et al.
Extensive research on estrogen identified estro- This was the first study to demonstrate the protective role of ERa non-nuclear signaling in cardiac function and remodeling to pathological stressors by Cardioprotective Roles of ER-a Non-Nuclear Signaling using pathway-specific deletion animals. It was reasonable to postulate that myocardial NO-cGMP-PKG might primarily contribute to the benefits from this signaling; however, it remains to be determined which cell type is the key to the estrogen-elicited NOcGMP-PKG in the heart. Our previous work demonstrated that short-term E2 application to isolated cardiomyocytes induced a cGMP increase in cardiac myocytes (10) . In the present study, we found that estrogen-stimulated NOS activity was absent in car- However, we speculate that androgens might function in male hearts, as do estrogens in female hearts.
For example, a previous study by Sieveking et al. (50) revealed that androgens played an important role in angiogenesis under ischemic stress of hind limbs in male mice but not in female mice. Yoshida et al. (51) reported that androgen signaling activated the Akt/ eNOS signaling pathway.
As a translational insight, our data could partially explain the negative results of clinical studies of Estrogen exerts physiological effects via genomic and non-genomic pathways. The non-nuclear pathway of ER a plays a pivotal role in heart failure remodeling.
An intact non-nuclear pathway is required for the therapeutic efficacy of cGMP-PDE5 inhibition in females, whereas estrogen status does not affect the efficacy of cGMP-sGC stimulation.
TRANSLATIONAL OUTLOOK:
The study might provide a potential explanation for the negative results of PDE5 inhibition in heart failure and might also provide a molecular basis for the advantage of using a sGC simulator as a new therapeutic option in postmenopausal women. This study also highlighted the need for a female-specific therapeutic strategy.
